EFFICACY OF GOLIMUMAB IN THE TREATMENT OF ANKYLOSING SPONDYLITIS AND RHEUMATOID ARTHRITIS (own experience)
DOI:
https://doi.org/10.31082/1728-452X-2020-215-216-5-6-24-31Keywords:
rheumatoid arthritis, ankylosing spondylitis, golimumab, efficacyAbstract
Genetic engineering drugs are used to treat rheumatic diseases. Based on the results of multicenter studies, the effectiveness and safety of golimumab, a representative of the group of tumor necrosis factor inhibitors in various categories of patients, was proved..
Purpose of research.To evaluate the effectiveness of golimumab in the treatment of ankylosing spondylitis and rheumatoid arthritis.
Material and methods.The efficacy of golimumab was analyzed based on clinical and laboratory data in 7 patients with ankylosing spondylitis and 6 patients with rheumatoid arthritis. These studies are described against the background of a one-year follow-up of patients.
Results and discussion. The observation group consisted of 7 patients with ankylosing spondylarthritis (as) and 6 patients with a diagnosis of rheumatoid arthritis. In all patients with (as) at the beginning of the study, the BASDAI index >6 points, and in 5 patients, the ASDASRB index was 3.5±0.45. In 4 patients with the diagnosis (as), the BASFI index was 7±0.67, and in three patients-5±0.3. the BASMI Index in all studied patients revealed pronounced disorders and was 7.5±0.85. Positive dynamics was observed during golimumab therapy. A patient with a high degree of BASDAI activity >6 showed improvement on the 4th injection of golimumab, the Average score of BASDAI and BASFI indices on golimumab was lower by the 20th week, compared with the start of therapy. By the 24th week of therapy, the BASDAI index was down 31%.
The follow-up group with the diagnosis of rheumatoid arthritis consisted of 6 patients, including 1 male and 5 female, with an average age of 38±0.5 years. In a male patient, the DAS-28 index was 5.2±0.06, the SDAI index was 27±0.05, and the CDAI index was 23±0.03. In women, the DAS-28 index was 3.8±0.03, and the SDAI index was 19±0.3 in 5 patients, and the CDAI index was 20±0.3. after adding golimumab, the General condition of all patients improved clinically after the second injection, and all indicators of inflammatory activity decreased. Golimumab is a human monoclonal antibody to tumor necrosis factor (TNF)α. The effect of golimumab is due to the binding and neutralization of soluble and membrane-bound forms of TNF)α. TNF)α. it is a cytokine detected in patients with rheumatoid arthritis, ankylosing spondylarthritis.
Conclusion. Against the background of the use of golimumab, the clinical effect was noted in the form of complete relief of joint pain and positive dynamics according to the studied laboratory parameters.
References
Revmatologiia. Rossiiskie klinicheskie rekomendatsii [Rheumatology. Russian clinical guidelines] Ed. EL Nasonov. M.:GEOTAR-Media; 2017. 464 p. ISBN 978-5-9704-4261-6
Chichasova NN. Golimumab for Treating Chronic Inflammatory Joint Diseases in the Adult Population: Clinical Efficacy and Tolerability. Voprosy sovremennoi pediatrii = Current Pediatrics. 2018;17(6):449-457. (In Russ.). DOI:10.15690/vsp.v17i6.1975
Godzenko AA, KorsakovaYuL, Badokin VV. Methods for the evaluation of inflammatory activity and therapy efficiency in spondyloarthritis. Sovremennaia revmatologiia = Modern Rheumatology Journal. 2012;6(2):66-76. (In Russ.) DOI: 10.14412/1996-7012-2012-730
Karateev DE. Golimumab in the treatment of inflammatory diseases: A role of immunogenicity. Sovremennaia revmatologiia = Modern Rheumatology Journal. 2015;9(4):20-24. (In Russ.). DOI: 10.14412/1996-7012-2015-4-20-24
Aleksandrova EN, Novikov AA, Nasonov EL. Role of laboratory biomarkers in monitoring and prediction of the effectiveness of treatment of rheumatic diseases using genetically engineered drugs. Sovremennaia revmatologiia = Modern Rheumatology Journal. 2014;8(1):5-13. (In Russ.). DOI: 10.14412/1996-7012-2014-1-5-13
Karateev DE. The problems of THE immunogenicity of biologicals: theory and practice. Sovremennaia revmatologiia = Modern Rheumatology Journal. 2009;3(1):67-72. (In Russ.). DOI: 10.14412/1996-7012-2009-527
Karateev DE. How real is the long-lasting effect of tumor necrosis factor α inhibitors? Focus on immunogenicity. Sovremennaia revmatologiia = Modern Rheumatology Journal. 2014;8(2):35-40.
(In Russ.). DOI: 10.14412/1996-7012-2014-2-35-40
Chichasova NV. The tumor necrosis factor-α inhibitor golimumab in the treatment of rheumatoid arthritis. Sovremennaia revmatologiia = Modern Rheumatology Journal. 2014;8(4):76-85. (In Russ.). DOI: 10.14412/1996-7012-2014-4-76-85
Smirnov AV, Dubinina TV, Erdes SF. Efficacy of golimumab in the treatment of patients with ankylosing spondylitis (according to the data of a long-term follow-up). Sovremennaia revmatologiia = Modern Rheumatology Journal. 2015;9(1):72-77. (In Russ.). DOI: 10.14412/1996-7012-2015-1-72-77
Nasonov EL, Karateev DE, Balabanova RM. Revmatoidnyiartrit. Natsionalnoerukovodstvo [Rheumatoid arthritis.National leadership]. Ed. EL Nasonova, VA Nasonova. - Moscow: GEOTAR-Media; 2008 P. 290-331
Alexandrova EN, Nasonov EL. Immunologiiarevmatoidnogoartrita. V kn.: Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita [Immunology of rheumatoid arthritis. In the book: Genetic engineering biological preparations in the treatment of rheumatoid arthritis]. Ed. EL Nasonov. - Moscow: IMA-Press; 2013. P. 19-46
Braun J, Deodhar A. Inmaun RD, et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis:104-week results of the GO-RAISE study. Ann Rheum Dis. 2012;71(5):661-667. DOI: 10.1136/ard2011/154799
Deodhar A, Braun J, Inmaun RD, et al Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study. Ann Rheum Dis. 2015 Apr;74(4):757-61. DOI: 10.1136/annrheumdis-2014-205862
Braun J, Baraliakos X, Hermann KG, et al The effect off two golimumab doses on radiographic progression in ankylosing spondylitis; results through 4 years of the GO-RAISE tria. Ann Rheum Dis. 2014;73(6):1107-1113. DOI: 10.1136/ annrheumdis-2012-203075
Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid artritis despite methotrexate therapy: the GO-FORWARD trial. J Rheumatol. 2016;43(2):298-306. DOI: 10.3899/j.rheum.150712
Singh JA,Wells GA, Christensen R, et al. Adverse tffects jf biologicsa network metanalysis and Cochrane overview. Cochrane Database Syst Rev. 2011 Feb 16;2011(2):CD008794. DOI: 10.1002/14651858.CD008794.pub2
Fausel R,Afzali A.Biologics in the managemtnt of ulcerative colitis- comparative safety and efficacy of TNF-α antagonists. Ther Clin Risk Manag. 2015 Jan 5;11;63-73.doi:10.2147/TCRM.S55506.
Pereira R,Lago P, Faria R, Torres T. Saffety of Anti-TNF Therapies in immune-mediated inflammatory Diseases Focus on Infections and Malignancy. Drug Dev Res. 2015 Oct 20.
Perez Ruixo JJ, Ma P, Chow AT.The utility of modeling and simulation approaches to evaluate immunogenicity effect on the therapeutic protein pharmacokinetics. AAPS J. 2013 Jan;15(1):172-82. DOI: 10.1208/s12248-012-9424-8
